By Michael Le Page Rat on cobbled street in cityEyeEm / Alamy We are changing the world in a way that favours animals such as bats – the source of the new coronavirus – that carry more diseases. That is the conclusion of an analysis looking at what changes are occurring in ecosystems as people…
By Michael Le Page Wild hummingbirds were able to distinguish between bird feeders by looking at the colours emitted by a special lightNoah Whiteman Birds, reptiles, amphibians and fish may see kinds of colours we cannot even imagine, say researchers whose experiments with wild hummingbirds show they perceive five so-called non-spectral colours. Almost all of…
By Michael Marshall Humpback whales may benefit from a lack of cruise shipsDave Fleetham/Zuma Press/PA Images Overall, the pandemic poses many threats to wildlife worldwide, as conservation programmes struggle for funding and poachers make the most of reduced patrols. But there are some instances in which coronavirus restrictions may be benefitting certain species. Some of…
By Layal Liverpool Drunk bats would be a flight risk KEVIN ELSBY/Alamy Humans, chimpanzees, gorillas, bats and other mammals with a diet that contains lots of fruit and nectar may be the best in the animal kingdom at metabolising their alcohol. Fruits and nectars are rich sources of energy that many animals rely on. However,…
Robert F. Kennedy Jr. has rightly made “radical transparency” the motto of his Department of Health and Human Services. HHS even has a page by that name. I think it is a good motto, and I want to help Secretary Kennedy and Acting FDA Commissioner Kyle Diamantas deliver on it in food safety, with two citizen petitions
Published: October 30, 2026, 10:16 pm Several reports of children choking have led to an FDA warning against Once Upon A Time snacks. The warning covers all flavors, quantities, lots and dates of Once Upon A Farm Tractor Wheels Organic, Toddler Soft-Baked Bars. The FDA has received several reports that describe infants ages 1.5 to
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment